Editor's Note: Green and red arrows refer to intraday stock price movement.NEW YORK ( TheStreet) -- STOCK COMMENTS / EPS CHANGES Agilent Technologies ( A) price target raised at Credit Suisse to $48 from $36 as global IP will drive revenue growth. Our best test and measurement idea, Credit Suisse said. Maintain Outperform rating. Apple ( AAPL) estimates, target raised at Deutsche . Shares of AAPL now seen reaching $410, according to Deutsche Bank. Estimates also increased, given higher expected iPhone and iPad sales. Buy rating. Apollo Group ( APOL) estimates lowered at UBS. 2011 EPS estimates lowered to $4.50 from $4.60. Maintains Neutral rating and $40 price target. Boston Scientific ( BSX) estimates lowered at Goldman through 2014. Neurovascular sale will cut into earnings. Sell rating and $6 price target. Chubb ( CB) price target boosted at Barclays to $59 from $55. CB is one of the best underwriters but its carriers a high valuation, Barclays said. Maintain Equal Weight rating. Clorox ( CLX) estimates, target reduced at Goldman. Shares of CLX now seen reaching $64. Estimates also lowered, given lower Staples sales. Neutral rating. Coventry Health Care ( CVH) price target raised at Credit Suisse by a dollar to $33. Sale by UAM highlights intrinsic value of PDP business, Credit Suisse said. Maintain Outperform rating. Walt Disney ( DIS) target upped at Morgan Stanley to $44. Company should see earnings accelerate in 2011. Overweight rating. Fiserv ( FISV) price target raised at Barclays to $60 from $58 after positive meeting with management regarding the company's growth trajectory, Barclays said. Maintain Equal Weight rating. Global Payments ( GPN) numbers boosted at Goldman. Shares of GPN now seen reaching $44. Estimates also upped, as higher sales should drive wider margins. Neutral rating. Grainger ( GWW) numbers raised at UBS. Price target raised to $140 from $135. 2011 EPS estimates raised to $7.70 from $7.55. Maintains Neutral rating. ITC Holdings Corp ( ITC)price target boosted at Credit Suisse. ITC price target raised to $72 from $63. Growth combined with stability set up promising 2011. Maintain Outperform rating. Johnson & Johnson ( JNJ) numbers lowered at Goldman through 2013. Company is likely to experience a slower recovery. Neutral rating and new $59 price target.